The first of its kind in Japan, the Global Health Innovative Technology Fund (GHIT Fund) is between seven Japanese pharmaceutical companies, the Japanese
Government, the Bill & Melinda Gates Foundation, the Wellcome Trust, and UNDP. Launched in April 2013 with an initial commitment of more than US$100
million, the organization taps Japanese research and development (R&D) to fight neglected diseases. The GHIT Fund invests and manages a portfolio of
development partnerships aimed at neglected diseases that afflict the world's poorest people. GHIT mobilizes Japanese pharmaceutical companies and academic
and research organizations to engage in the effort to get new medicines and vaccines to people who need them most, with Japan quickly becoming a game-changer
in global health.